Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
XPhyto Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
XPhyto Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XPhyto Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare XPhyto Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare XPhyto Therapeutics's earnings growth to the Canada market average as no estimate data is available.
Unable to compare XPhyto Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if XPhyto Therapeutics is high growth as no earnings estimate data is available.
Unable to determine if XPhyto Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
XPhyto Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
XPhyto Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
XPhyto Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
XPhyto Therapeutics's long term commitments exceed its cash and other short term assets.
This treemap shows a more detailed breakdown of
XPhyto Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 2.5x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Hugh A.D. Rogers, B.Sc., LL.B has been the Chief Executive Officer at Coronado Resources Ltd. since March 6, 2015. Mr. Rogers serves as the Chairman of the Board at Telo Genomics Corp. (formerly known as 3D Signatures Inc.). Mr. Rogers served the Interim Chairman of Telo Genomics Corp. (formerly known as 3D Signatures Inc.), since September 12, 2018. He serves as the Chief Executive Officer and President of Seashore Resource Partners Corp. and also as its Director since November 13, 2017. He served as Chief Executive Officer, Chief Financial Officer and President at Angus Ventures Inc. until July 25, 2017. He served as Vice President of Corporate Finance at 3D Signatures Inc., since April 2015. Since November 2011, Mr. Rogers has been self employed as a corporate finance consultant. He is a Co-Owner of SXR Capital Corp. He is an entrepreneur and lawyer with broad private and public company experience in corporate finance, business strategy, regulatory compliance and Investor Relations. He has corporate finance and restructuring experience through his work with various TSX-V listed issuers. From December 2012 to June 2013, he was responsible for business development of Huldra Silver Inc. From November 2011 to November 2012, Mr. Rogers served as a self-employed corporate development consultant located in Vancouver, British Columbia. From April 2011 to October 2011, he served as Corporate Counsel for Zimtu Capital Corp., a corporation that invests in mining and resources. From May 2010 to March 2011, he was self-employed as an attorney specializing in litigation. From May 2009 to April 2010, he was an Articled Student for Legal Services Society of British Columbia. He has been Director at Kootenay Zinc Corp., since September 2016. He has been a Director of Coronado Resources Ltd. since March 6, 2015. He served as Director of RepliCel Life Sciences Inc. since February 3, 2017 to December 14, 2018. He was a Director of Vizsla Resources Corp. from September 26, 2017 to January 2019. He served as Director at Angus Ventures Inc. He served as Independent Director of McorpCX, Inc. since November 20, 2015 until February 1, 2017. He is an active Member of The Law Society of British Columbia Mr. Rogers is an attorney licensed to practice law in British Columbia. He is a Member in good standing of the Law Society of British Columbia. Mr. Rogers served as Outside Director at Clear Blue Technologies International Inc. until June 17, 2019. Mr. Rogers serves as a President and Chief Executive Officer and Director at Xphyto Therapeutics Corp., since December 2017. He holds a B.Sc. degree from the University of British Columbia and holds a Legum Baccalaureus (LLB) degree from University of New Brunswick. His corporate finance, restructuring and regulatory experience has been primarily focused on start-ups and small cap companies in the resource and biotechnology industries.
Insufficient data for Hugh to compare compensation growth.
Insufficient data for Hugh to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Chief Financial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the XPhyto Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Do Insiders Own Lots Of Shares In XPhyto Therapeutics Corp. (CNSX:XPHY)?
Taking a look at our data on the ownership groups (below), it's seems that institutions don't own shares in the company. … See our latest analysis for XPhyto Therapeutics CNSX:XPHY Ownership Summary, August 7th 2019 What Does The Lack Of Institutional Ownership Tell Us About XPhyto Therapeutics? … General Public Ownership The general public, who are mostly retail investors, collectively hold 85% of XPhyto Therapeutics shares.
XPhyto Therapeutics Corp., through its subsidiaries, operates in the medicinal cannabis industry in Canada and Germany. It is involved in the production, extraction, isolation, formulation, delivery, marketing, and sale of medicinal cannabis. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.